Eravacycline FDA approved

The US FDA has approved eravacycline to treat “complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.” The company plans to launch the drug in the US in October.

In another development, the FDA’s Antimicrobials Drug Advisory Committee has voted in favor of approving omadacycline for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Omadacycline is a once-daily, IV and oral, broad-spectrum antibiotic in the tetracycline family. Final approval decision is awaited.